<DOC>
	<DOCNO>NCT01097148</DOCNO>
	<brief_summary>Rationale : Obesity increase health risk worldwide , USA record prevalence adult around 20 % . The mean body weight obese patient also increase . One strategies treat extreme obesity ( Body Mass Index ( BMI ) &gt; 40 kg/m2 ) weight-reducing surgery like laparoscopic gastric band gastric bypass . During anaesthesia , morbidly obese patient expose increase risk develop postoperative wound infection , apnoea thrombotic event may difficult intubate . Routinely , amongst others , cefazolin , morphine , nadroparin atracurium administer standard dosage . However , know extend pharmacokinetics and/or -dynamics drug affect morbidly obese patient . Therefore , evidence-based dosing schedule drug morbidly obese patient develop . Objective : The study perform order develop population pharmacokinetic and/or pharmacodynamic model routinely use drug therapy bariatric surgery morbidly obese patient ( BMI &gt; 40 kg/m2 ) : cefazolin , morphine , nadroparin atracurium . A covariate analysis perform order account variability pharmacokinetic and/or pharmacodynamic parameter . This covariate analysis take account procedure patient bound covariates , specific interest body weight covariate . Whenever possible , non-obese patient include covariate analysis . The result use develop individualised dosing scheme routinely use drug peri-operatively morbidly obese patient . Study design : A randomised , prospective , observational , therapeutic invasive study . Study population : Morbidly obese patient Body Mass Index &gt; 40 kg/m2 undergo laparoscopic band gastric bypass surgery , 18-60 year old . A total 20 patient include study . Intervention ( applicable ) : All measurement data collection take place around administration drug give accord routine clinical practice ( cefazolin 2 gram prophylaxis infection , morphine 10 mg intravenously end surgery , patient-controlled analgesia ( PCA ) pump morphine postoperative pain relief nadroparin 0,6 ml trombo-embolic prophylaxis ) . For muscle relaxation , patient randomise receive one two generally accept dose regimen atracurium ( 0.5 mg/kg base ideal body weight 0.5 mg/kg base total body weight ) . Peri- postoperatively , maximum amount 70 ml blood collect indwell arterial line measurement concentration cefazolin , morphine , anti-Xa ( nadroparin ) . One week surgery patient check thrombosis use ultrasonography . Main study parameters/endpoints : Primary endpoint evaluate morbidly obese patient ; - pharmacokinetic parameter cefazolin blood ; - pharmacokinetic parameter morphine metabolite blood ; - time course anti-factor Xa level blood follow nadroparin ; - time course pharmacodynamic effect atracurium . Secondary endpoint evaluate morbidly obese patient : - compare primary endpoint ( obtain morbidly obese patient ) data non-obese patient - occurrence postoperative wound infection ; - postoperative pain score , sedation score nausea score ; - occurrence bleeding thrombotic event ; - require amount morphine ( PCA ) ; - compare time course pharmacodynamic effect two different dos atracurium .</brief_summary>
	<brief_title>Peri -and Postoperative Drug Therapy Schedules Morbidly Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Atracurium</mesh_term>
	<criteria>Morbidly obese patient undergo bariatric surgery BMI &gt; 40 kg/m2 , ASA IIII Epilepsy , pregnancy , breastfeed know allergy allergy cefazolin , morphine , nadroparin , atracurium , benzene sulphonic acid . History coagulation disorder history heparin/LMWH induce thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Obese</keyword>
	<keyword>Atracurium</keyword>
	<keyword>Cefazolin</keyword>
	<keyword>Morfine</keyword>
	<keyword>Nadroparin</keyword>
</DOC>